Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...

Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

AI technologies are revolutionizing healthcare, driving personalized care, efficient health management, and faster drug discovery. Physicians benefit from AI-assisted diagnosis and treatment ...

The U.S. pays more for prescription medicines than any other country, and incoming President Donald Trump has vowed to lower drug costs by focusing on middlemen in the U.S. healthcare system.

He has worked with Torrent Pharmaceuticals and Cadila Pharmaceuticals, and also with Reliance Retail and Corporate IT Park. He holds a degree in industrial engineering and is responsible for ...

While Democrats are known to push for lower drug prices in the US, over the past few years, even Republicans are talking about keeping the cost of healthcare low. If costs have to be low, there cannot ...

But how much does health insurance actually cost us? According to the American Medical Association, it’s just 6 percent of health care spending. In other words, if insurers were to donate every ...